학술논문
High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.
Document Type
Journal Article
Author
Allenbach, Yves; Keraen, Jeremy; Bouvier, Anne-marie; Jooste, Valérie; Champtiaux, Nicolas; Hervier, Baptiste; Schoindre, Yoland; Rigolet, Aude; Gilardin, Laurent; Musset, Lucile; Charuel, Jean-Luc; Boyer, Olivier; Jouen, Fabienne; Drouot, Laurent; Martinet, Jeremie; Stojkovic, Tanya; Eymard, Bruno; Laforêt, Pascal; Behin, Antony; Salort-Campana, Emmanuelle
Source
Subject
*CANCER risk factors
*AUTOIMMUNE diseases
*MUSCLE diseases
*MYOSITIS
*DERMATOMYOSITIS
*DISEASE incidence
*AUTOANTIBODIES
*COMPARATIVE studies
*RESEARCH methodology
*MEDICAL cooperation
*OXIDOREDUCTASES
*RESEARCH
*TUMORS
*COMORBIDITY
*EVALUATION research
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0006-8950
Abstract
Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specifically associated with necrotizing autoimmune myopathies. We aimed at screening the incidence of cancer in necrotizing autoimmune myopathies. A group of patients (n = 115) with necrotizing autoimmune myopathies with or without myositis-specific antibodies was analysed. Malignancy occurred more frequently in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients compared to anti-signal recognition particle positive patients. Synchronous malignancy was diagnosed in 21.4% and 11.5% of cases, respectively, and incidence of cancer was higher compared to the general population in both groups. No specific type of cancer was predominant. Patients suffering from a synchronous cancer had a decreased median survival time. Cancer screening is necessary in seronegative necrotizing autoimmune myopathies and in HMGCR-positive patients but not in anti-signal recognition particle-positive patients. [ABSTRACT FROM AUTHOR]